These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 28283035)
1. Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia. Lu Z; Xu N; He B; Pan C; Lan Y; Zhou H; Liu X J Exp Clin Cancer Res; 2017 Mar; 36(1):43. PubMed ID: 28283035 [TBL] [Abstract][Full Text] [Related]
2. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326 [TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124 [TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells. He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093 [TBL] [Abstract][Full Text] [Related]
5. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856 [TBL] [Abstract][Full Text] [Related]
7. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells. Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592 [TBL] [Abstract][Full Text] [Related]
8. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia. Chen Y; Wang T; Du J; Li Y; Wang X; Zhou Y; Yu X; Fan W; Zhu Q; Tong X; Wang Y Cell Physiol Biochem; 2018; 47(3):981-993. PubMed ID: 29843123 [TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis. Jiang Y; Xiao S; Huang S; Zhao X; Ding S; Huang Q; Xiao W; Li Z; Zhu H Hematology; 2024 Dec; 29(1):2379597. PubMed ID: 39056503 [TBL] [Abstract][Full Text] [Related]
10. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression. Tan Z; Peng A; Xu J; Ouyang M BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554 [TBL] [Abstract][Full Text] [Related]
11. AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia. Medeiros HCD; Colturato-Kido C; Ferraz LS; Costa CA; Moraes VWR; Paredes-Gamero EJ; Tersariol ILS; Rodrigues T Chem Biol Interact; 2020 Jan; 315():108888. PubMed ID: 31682805 [TBL] [Abstract][Full Text] [Related]
12. TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway. Li L; Qi Y; Ma X; Xiong G; Wang L; Bao C Cell Biol Int; 2018 Sep; 42(9):1192-1199. PubMed ID: 29762880 [TBL] [Abstract][Full Text] [Related]
13. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
15. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649 [TBL] [Abstract][Full Text] [Related]
16. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. Yuan R; Chang J; He J Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790 [TBL] [Abstract][Full Text] [Related]
17. Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway. Cao L; Wang J; Ma D; Wang P; Zhang Y; Fang Q Biomed Pharmacother; 2016 Mar; 78():30-38. PubMed ID: 26898422 [TBL] [Abstract][Full Text] [Related]